Laura Williams Sells 8,176 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider Laura Williams sold 8,176 shares of Ardelyx stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $5.85, for a total transaction of $47,829.60. Following the completion of the transaction, the insider owned 436,082 shares in the company, valued at approximately $2,551,079.70. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ardelyx Trading Up 14.1%

NASDAQ ARDX opened at $6.56 on Wednesday. The firm’s 50 day moving average price is $6.77 and its two-hundred day moving average price is $6.14. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -26.24 and a beta of 0.57. The company has a debt-to-equity ratio of 1.21, a quick ratio of 4.11 and a current ratio of 4.31. Ardelyx, Inc. has a twelve month low of $3.21 and a twelve month high of $8.40.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. The company had revenue of $125.22 million for the quarter, compared to analyst estimates of $118.04 million. During the same period last year, the business earned $0.02 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts anticipate that Ardelyx, Inc. will post -0.18 EPS for the current year.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott bought 333,333 shares (~$1.95M) at about $5.84, increasing his stake ~11.2% — a strong insider vote of confidence that can support the stock. Read More.
• Positive Sentiment: Ardelyx announced a multi‑year partnership with the LPGA to raise awareness and reduce stigma around digestive health — a marketing push that could help commercial uptake of XPHOZAH/brand awareness over time. Read More.
• Positive Sentiment: Analyst support remains strong — Wedbush reaffirmed an outperform with a $19 target and other firms (BTIG, HC Wainwright, Jefferies, Citi) have reiterated buys or raised targets, which can attract buyers. Read More. Read More.
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and revenue grew ~7.8% y/y — constructive fundamental data but partially offset by the EPS miss.
• Neutral Sentiment: Post‑results commentary includes valuation and guidance analysis (coverage piece on Yahoo Finance reviewing 2025 results and 2026 guidance) — useful for longer‑term investors assessing upside vs. risk. Read More.
• Negative Sentiment: Ardelyx missed EPS expectations (reported a small loss vs. a modest expected profit), which triggered a post‑earnings pullback and adds short‑term risk for the shares. Read More.
• Negative Sentiment: Multiple insiders (including CEO Michael Raab, CFO Susan Hohenleitner and several executives) sold shares around Feb. 20 (CEO sold ~45,982 shares), which can be perceived as profit‑taking and may pressure sentiment despite the director buy. Read More.

Hedge Funds Weigh In On Ardelyx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its position in shares of Ardelyx by 23.1% in the fourth quarter. Invesco Ltd. now owns 317,410 shares of the biopharmaceutical company’s stock valued at $1,851,000 after buying an additional 59,597 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Ardelyx by 4.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 1,722 shares in the last quarter. Mackenzie Financial Corp lifted its stake in Ardelyx by 12.8% in the 4th quarter. Mackenzie Financial Corp now owns 199,550 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 22,715 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Ardelyx by 1,690.9% during the 4th quarter. NewEdge Advisors LLC now owns 17,909 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 16,909 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Ardelyx during the fourth quarter valued at about $698,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ARDX. Weiss Ratings restated a “sell (d-)” rating on shares of Ardelyx in a research note on Wednesday, January 21st. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Ardelyx in a research report on Friday, February 20th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $19.00 price target on shares of Ardelyx in a report on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Ardelyx in a report on Thursday, January 29th. Finally, Citigroup raised their target price on shares of Ardelyx from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.09.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.